Posted on April 24th, 2015 by
Class: Biological Therapy
Generic Name: palbociclib
Trade Name: Ibrance®
For which conditions is this drug approved? Ibrance is approved in combination with the medicine Femara® (letrozole) for the treatment of postmenopausal women with advanced breast cancer that is estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative for first therapy. It is also used in combination with Faslodex® (fulvestrant) in women with disease progression following hormonal therapy.
What is the mechanism of action? Ibrance is a kinase inhibitor. These drugs work by blocking the action of enzymes called kinases, which are involved in many cell functions, including cell signaling, growth, and division. These enzymes may be too active or found at high levels in some types of cancer cells, and blocking them may help keep cancer cells from growing. Specifically, Ibrance inhibits cyclin-dependent kinase (CDK) 4 and 6.
How is Ibrance typically given (administered)? Ibrance is given as a capsule. Take Ibrance with food and in combination with Femara.
How are patients typically monitored? Your doctor will perform regular blood test to check for neutropenia (low count of neutrophils, a type of white blood cell that helps fight off infections). Your doctor will also check you for signs of infection.
What are the common (occur in 30% or more of patients) side effects of treatment with Ibrance?
What are the less common (occur in 10% to 29% of patients) side effects of treatment with Ibrance?
This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.
Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?
Are there any special precautions patients should be aware of before starting treatment?
When should patients notify their physician?
What is a package insert? A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.
You must be logged-in to the site to post a comment.